Trial intelligence / Profile preview

Procysteine in HIV-Infected Patients

NCT00002114Phase 2

Key facts

Status: Completed
Modality: Small Molecules

Drugs: Oxothiazolidinecarboxylic acid
Conditions: human immunodeficiency virus infection (HIV)

Overview

Phase 2, randomised, double-blind trial of Oxothiazolidinecarboxylic acid in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoints: Efficacy at 30 weeks and Safety at 30 weeks. Status: completed.

Design

3 arms

Study design: RandomizedDouble-blind

Placebo
Placebo + Background ARV
Low Dose Procysteine
Low Dose Procysteine + Background ARV
High Dose Procysteine
High Dose Procysteine + Background ARV

Who it enrols

HIV-infected patients with CD4 counts between 50-300 cells/mm3 (or 50-200 if asymptomatic/KS) who have been on stable antiretroviral nucleoside therapy for at least 3 months.

Endpoints

Primary

Efficacy30 weeks
Safety30 weeks

Beyond the preview

Go deeper on NCT00002114.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00002114.